A postmenopausal woman has ER-positive, HER2-negative metastatic breast cancer with an activating ESR1 mutation. Disease progressed after 14 months

Question

A postmenopausal woman has ER-positive, HER2-negative metastatic breast cancer with an activating ESR1 mutation. Disease progressed after 14 months of an aromatase inhibitor plus a CDK4/6 inhibitor. Which current NICE option is specifically biomarker-directed?

Accepted Answer

Use elacestrant because the 12-month endocrine plus CDK4/6 criterion is met

Answer

Use elacestrant after demonstrating concurrent HER2 amplification on the current biopsy

Answer

Use elacestrant after one cytotoxic regimen for metastatic disease has been completed

Answer

Use elacestrant because the prior CDK4/6 exposure was shorter than the qualifying duration

Answer

Use fulvestrant because an ESR1 mutation excludes oral SERD treatment in the NHS

Melanoma — SCE Medical Oncology MCQ

A postmenopausal woman has ER-positive, HER2-negative metastatic breast cancer with an activating ESR1 mutation. Disease progressed after 14 months of an aromatase inhibitor plus a CDK4/6 inhibitor. Which current NICE option is specifically biomarker-directed?